Review: Free fatty acid receptors: emerging targets for treatment of diabetes and its complications
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Fatty acids (FAs) are important as metabolic substrates and as structural components of biological membranes. However, they also function as signalling molecules. Recently, a series of G protein-coupled receptors (GPRs) for FAs has been described and characterized. These receptors have differing specificities for FAs of differing chain length and degree of saturation, for FA derivatives such as oleoylethanolamide, and for oxidized FAs. They are a critical component of the body’s nutrient sensing apparatus, and small molecule agonists and antagonists of these receptors show considerable promise in the management of diabetes and its complications. Agonists of the long-chain free fatty acid receptors FFAR1 and GPR119 act as insulin secretagogues, both directly and by increasing incretins. Although, drugs acting at short-chain FFA receptors (FFAR2 and FFAR3) have not yet been developed, they are attractive targets as they regulate nutrient balance through effects in the intestine and adipose tissue. These include regulation of the secretion of cholecystokinin, peptide YY and leptin. Finally, GPR132 is a receptor for oxidized FAs, which may be a sensor of lipid overload and oxidative stress, and which is involved in atherosclerosis. Regulation of its signalling pathways with drugs may decrease the macrovascular risk experienced by diabetic patients. In summary, FA receptors are emerging drug targets that are involved in the regulation of nutrient status and carbohydrate tolerance, and modulators of these receptors may well figure prominently in the next generation of antidiabetic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
Butyrate improves insulin sensitivity and increases energy expenditure in mice
Gao, Z., Yin, J., Zhang, J., Ward, R. E., Martin, R. J., Lefevre, M., Cefalu, W. T., & Ye, J. (2009) · Diabetes · doi:10.2337/db08-1637 · Cited by 2,204 · cited 1×
“In a recent study [Gao et al. 2009], butyrate administration to mice led to improved systemic insulin sensitivity.”
BackgroundInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 2×
“1998], and its release is accompanied by decreased appetite and decreased food intake through actions in the central nervous system [Batterham et al. 2003].”
BackgroundFree fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538 · cited 1×
“FFAR1 was described independently by three groups [Briscoe et al. 2003; Itoh et al. 2003; Kotarsky et al. 2003].”
MethodA human cell surface receptor activated by free fatty acids and thiazolidinedione drugs
Kotarsky, K., Nilsson, N. E., Flodgren, E., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03064-4 · Cited by 352 · cited 10×
“Receptors for FFAs have emerged as an important component of this apparatus and evidence is emerging that pharmacological manipulation of these pathways could contribute to the management of type 2 diabetes (Figure 2).”
BackgroundMethodInfluentialParker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324 · cited 2×
“The most important sites for FFAR1 expression are the insulin-secreting b cells, the K and L cells of the small and large intestine respectively, splenocytes and peripheral blood mononuclear cells [Morgan et al. 2009; Parker et al. 2009].”
Background
Cited by
The role of short chain fatty acids in health and disease
Tan, J., McKenzie, C., Potamitis, M., Thorburn, A. N., Mackay, C. R., & Macia, L. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800100-4.00003-9 · Cited by 2,425
Kaczmarczyk, M. M., Miller, M. J., & Freund, G. G. (2012) · Metabolism · doi:10.1016/j.metabol.2012.01.017 · Cited by 554
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Fatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells During Development of Type 2 Diabetes
Oh, Y. S., Bae, G. D., Baek, D. J., Park, E.-Y., & Jun, H.-S. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00384 · Cited by 306
Stanley, D., Hughes, R. J., Geier, M. S., & Moore, R. J. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00187 · Cited by 283
Metadata
- Authors
- Lee Kennedy, R., Vangaveti, V., Jarrod, G., Shashidhar, V., Shashidhar, V., & Baune, B. T.
- Venue
- Therapeutic Advances in Endocrinology and Metabolism
- Publisher
- SAGE Publications
- Published
- 2010-08-16
- Volume
- 1
- Issue
- 4
- Pages
- 165-175
- ISSN
- 2042-0188 (ISSN-L)
- 2042-0196
- OpenAlex
- W2104742442
- Cited by
- 67
- References
- 6
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review: Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. https://app.cochat.ai/papers/10.1177/2042018810381066
- The paper
- Lee Kennedy, R., Vangaveti, V., Jarrod, G., Shashidhar, V., Shashidhar, V., & Baune, B. T. (2010). Review: Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/2042018810381066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.